There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NeoGenomics (NEO – Research Report), Wave Life Sciences (WVE – Research Report) and Ardelyx (ARDX – Research Report) with bullish sentiments.
Discover the Best Stocks and Maximize Your Portfolio:
NeoGenomics (NEO)
Leerink Partners analyst Puneet Souda maintained a Buy rating on NeoGenomics on February 19 and set a price target of $25.00. The company’s shares closed last Friday at $11.10, close to its 52-week low of $10.69.
According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of -12.3% and a 30.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Twist Bioscience, and Myriad Genetics.
Currently, the analyst consensus on NeoGenomics is a Moderate Buy with an average price target of $18.56, representing a 54.3% upside. In a report issued on February 12, Craig-Hallum also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Wave Life Sciences (WVE)
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Wave Life Sciences on February 18 and set a price target of $24.00. The company’s shares closed last Friday at $11.13.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 13.4% and a 43.5% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wave Life Sciences with a $22.67 average price target.
Ardelyx (ARDX)
In a report issued on February 20, Roanna Ruiz from Leerink Partners maintained a Buy rating on Ardelyx, with a price target of $12.00. The company’s shares closed last Friday at $5.06, close to its 52-week low of $4.32.
According to TipRanks.com, Ruiz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.5% and a 32.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Lexicon Pharmaceuticals, and Enanta Pharmaceuticals.
Ardelyx has an analyst consensus of Moderate Buy, with a price target consensus of $9.75, a 70.2% upside from current levels. In a report issued on February 20, TD Cowen also maintained a Buy rating on the stock with a $12.00 price target.
Read More on NEO: